Clinical trials in Britain have resumed for the Astrazeneca and Oxford University COVID-19 vaccine after the Medicines Health Regulatory Authority (MHRA) certified that it was safe to do so, reported Reuters.
The late stage trials of the vaccine, which is at one of the most advanced stages of development compared to other vaccines in the world, was stopped last week after a study subject in Britain developed an illness.
"The standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators," said Astrazeneca.
“The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume,” it added
"All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards," the company added, saying that it can reveal no other medical information.
(With inputs from Reuters)
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)